Last mentioned: Mar 13, 2026
Clinical Catalyst
Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
C$41.00 Target Confirmed
RBC and other major outlets confirm the new C$41.00 price target for TSE:ARE.
Analyst Revisions Begin
Initial reports of price target upgrades surface following strong guidance.
Analyst Target Cuts
TD Cowen and Canaccord Genuity slash price targets citing competitive risks and valuation.
Dividend Increase
Aecon Group announces a 1.3% hike in quarterly dividend to CAD 0.1925.
Market Volatility
VEEV stock surges 11% on long-term outlook before retreating on disclosure concerns.
Q4 Earnings Report
Veeva reports advancing income and sets a $6B revenue target for 2030.
Competitive Disclosure
Management reveals competitive losses in the CRM segment during the earnings call.
52-Week High
EWTX stock reaches a new yearly peak amid clinical pipeline optimism.
Analyst Upgrade
Wall Street Zen raises Edgewise Therapeutics to a 'Hold' rating.
Royal Bank of Canada has increased its price target for Aecon Group to C$41.00, following a dividend hike and robust performance in its core segments. The move reflects growing confidence in Aecon's ability to capitalize on large-scale Canadian infrastructure and energy transition projects.
Veeva Systems (VEEV) is navigating a complex post-earnings landscape as major analysts, including TD Cowen and Canaccord Genuity, significantly lower their price targets. Despite a bullish long-term revenue outlook, recent management disclosures regarding competitive losses have triggered a wave of valuation adjustments across Wall Street.
Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.